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Tfam Transcription factor A
AIM To provide a detailed gene and protein expression analysis related to mitochondrial
biogenesis and assess mitochondrial content in skeletal muscle of children with cerebral
palsy (CP).
METHOD Biceps brachii muscle samples were collected from 19 children with CP (mean [SD]
age 15y 4mo [2y 6mo], range 9–18y, 16 males, three females) and 10 typically developing
comparison children (mean [SD] age 15y [4y], range 7–21y, eight males, two females). Gene
expression (quantitative reverse transcription polymerase chain reaction [PCR]),
mitochondrial DNA (mtDNA) to genomic DNA ratio (quantitative PCR), and protein
abundance (western blotting) were analyzed. Microarray data sets (CP/aging/bed rest) were
analyzed with a focused query investigating metabolism- and mitochondria-related gene
networks.
RESULTS The mtDNA to genomic DNA ratio was lower in the children with CP compared to
the typically developing group (23%, p=0.002). Out of five investigated complexes in the
mitochondrial respiratory chain, we observed lower protein levels of all complexes (I, III, IV,
V, 20% to 37%; p<0.05) except complex II. Total peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC1a) messenger RNA (p<0.004), isoforms PGC1a1 (p=0.05),
and PGC1a4 (p<0.001) were reduced in CP. Transcriptional similarities were observed
between CP, aging, and 90 days’ bed rest.
INTERPRETATION Mitochondrial biogenesis, mtDNA, and oxidative phosphorylation protein
content are reduced in CP muscle compared with typically developing muscle.
Transcriptional pathways shared between aging and long-term unloading suggests metabolic
dysregulation in CP, which may guide therapeutic strategies for combatting CP muscle
pathology.
Cerebral palsy (CP) is the most common cause of motor
impairment in children.1 Although the initial brain injury
is non-progressive, skeletal muscle function typically dete-
riorates over time.2 Skeletal muscles of individuals with CP
are small, weak, and compositionally different compared
with typically developing muscle. Specifically, increased
collagen content3 and intramuscular adipose tissue4 are
believed to contribute to poor muscle function in this pop-
ulation. Poor muscle quality is a well-described risk factor
for insulin resistance and development of type 2 diabetes5,6
and is typically associated with a reduced mitochondrial
content of the muscle.7 Whether the described
pathological findings in CP muscle influences metabolic
capacity of the tissue is not known.
A recent study by Zogby et al. investigated skeletal mus-
cle mitochondrial characteristics in CP muscle using an
immunohistochemical approach. According to fiber-type-
specific succinate dehydrogenase activity,8 their results
showed a similar succinate dehydrogenase activity per unit
area in both type I and type II fibers in individuals with
CP and typically developing individuals, suggesting that
muscle oxidative potential is preserved in children with
CP. Conversely, other studies reporting on fiber types in
the muscles of children with CP describe a clear slow to
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fast-fiber-type shift,9,10 indicative of a less oxidative pheno-
type of the muscle, as fast type IIx fibers contain fewer
mitochondria than slow type I fibers. Moreover, two skele-
tal muscle transcriptomics studies in children with CP11,12
indicate reduced messenger RNA levels of key genes
involved in skeletal muscle mitochondrial biogenesis, such
as AMP-activated protein kinase (AMPK) and transcription
factor A (Tfam), contrasting with the data of Zogby et al.
An accurate picture of the metabolic characteristics of CP
muscle is of great importance for developing the appropri-
ate therapeutics to counteract muscle dysfunction.
Given the discrepancies in the literature, we wanted to
use genomic, transcriptomic, targeted messenger RNA,
and protein-based approaches to investigate whether: (1)
mitochondrial DNA (mtDNA) abundance and protein
levels of oxidative phosphorylation (OXPHOS) enzymes,
as markers of mitochondrial content, are reduced in CP
muscle compared with typically developing muscle; (2)
gene and protein expression of factors involved in mito-
chondrial biogenesis are reduced in CP muscle compared
with typically developing muscle; and (3) gene networks
linked to mitochondrial biology and glucose metabolism
are downregulated in CP muscle compared with typically
developing muscle. In addition, CP gene networks were
compared with severe inactivity and aging data sets to
identify common themes with respect to metabolic dysreg-




Nineteen children and adolescents (mean [SD] age 15y
4mo [2y 6mo]; range 9–18y; 16 males, three females) with
CP, scheduled for surgical lengthening of the biceps bra-
chii tendon, were included in the study. All but one patient
had a developed contracture of the elbow flexor muscles,
resulting in an extension deficit of the elbow. Their gross
motor function was classified on a five-level scale according
to the Gross Motor Function Classification System, and
their ability to use their hands was classified on a five-level
scale according to the Manual Ability Classification Sys-
tem. For details on type of CP, clinical presentation (uni-
lateral/bilateral), sex, age, contracture, Gross Motor
Function Classification System level, and Manual Ability
Classification System level, see Table S1 (online support-
ing information). Skeletal muscle samples were obtained
intraoperatively under general anesthesia and were frozen
in isopentane cooled on liquid nitrogen. All children had
fasted for a minimum of 10 hours before surgery. Control
biceps brachii muscle samples were obtained post-mortem
from children and young adults who had sustained acci-
dental deaths (n=10, mean age 15y 1mo; range, 7–21y; two
females and eight males; Table S2, online supporting
information). All samples were stored in a freezer at
80C until analysis. Seventeen out of 19 samples were
available for DNA analysis and 14 out of 19 samples for
gene expression, although not all samples were from the
same individuals. Owing to limited muscle material, 9 out
of 19 samples and 11 out of 19 samples were available for
OXPHOS and Tfam protein analysis respectively.
RNA/DNA extraction, cDNA synthesis, and quantitative
polymerase chain reaction
Skeletal muscle biopsies (~25mg) were homogenized in
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) using a
handheld homogenizer (Omni International, Kennesaw,
GA, USA). RNA and DNA were extracted according to
the information provided by the manufacturer (Invitrogen).
RNA was quantified using a NanodropVR 2000 (Thermo
Scientific, Gothenburg, Sweden), and integrity assessed by
agarose gel electrophoresis. DNA was resuspended in
8mM NaOH, then centrifuged at 4°C at 12 000g to
remove insoluble material. The DNA was transferred to a
new tube and pH adjusted with HEPES. All samples were
stored at 20°C until further use. Five hundred nanograms
of RNA were reverse-transcribed with a VILO cDNA syn-
thesis kit (Invitrogen) according to the manufacturer’s rec-
ommendations. Fast SYBR Green Master Mix (Applied
Biosystems, Foster City, CA, USA) was used for quantita-
tive polymerase chain reaction (PCR) in a QuantStudio 3
Real-Time quantitative PCR Systems machine (Thermo
Fisher Scientific, Waltham, MA, USA). Quantitative PCR
data (total peroxisome proliferator-activated receptor
gamma coactivator 1-alpha [PGC1a] and splice variants
PGC1-a1, a2, a3, and a4)13 were normalized to the geo-
metric mean of three stable reference genes (GAPDH,
EMC7, VCP). Primer sequences are available in Table S3
(online supporting information). Melting curves were per-
formed for every primer pair to confirm a single-product
amplification. All samples were run in duplicates and quan-
titative reverse transcription PCR data were analyzed using
the 2DDCT method.
Quantification of mtDNA to genomic DNA
DNA was diluted to a concentration of 10ng/lL. Primers
for the myogenin promoter was used to quantify genomic
DNA and the mitochondrial gene cytochrome c oxidase I
for mtDNA as previously described.14 Quantitative reverse
transcription PCR was performed and analyzed as
described for muscle gene expression. Primer sequences
are available in Table S3.
Western blotting
Muscle samples (approximately 20mg) were homogenized
in radio-immuno-precipitation assay buffer (20ll radio-
immuno-precipitation assay/mg tissue) containing 150mM
NaCl; 10mM Tris-HCl (pH 7.8); 5mM ethylenediaminete-
traacetic acid (pH 7.4); 0.5% Na deoxycholate; 0.1%
sodium dodecyl sulfate; 1% Triton-X100; and 19
What this paper adds
• Cerebral palsy (CP) muscle contains fewer energy-generating organelles than
typically developing muscle.
• Gene expression in CP muscle is similar to aging and long-term bed rest.
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complete protease inhibitor cocktail (Roche Diagnostics,
Basel, Switzerland) using glass homogenizers. The homo-
genate was rotated gently at 4°C for 60 minutes, followed
by centrifugation at 4°C for 10 minutes (15 000g). All
chemicals were purchased from Sigma unless stated other-
wise (Sigma-Aldrich, St Louis, MO, USA). Protein concen-
tration was assessed with the detergent compatible protein
assay (Bio-Rad, Hercules, CA, USA) and lysates diluted (if
needed) with lysis buffer before mixing 3:1 with 49
Laemmli buffer (Bio-Rad) containing 10% b-
mercaptoethanol. All samples were heat-denatured for 10
minutes, cooled on ice, and stored at 20°C until further
use. Skeletal muscle homogenates (25lg protein/sample)
were separated by electrophoresis on 4% to 15% TGX cri-
terion sodium dodecyl sulfate–PAGE gels (Bio-Rad) and
proteins were then transferred onto polyvinylidene difluo-
ride membranes (Bio-Rad). The membranes were blocked
at room temperature with Everyblot blocking buffer (Bio-
Rad) and then incubated with primary antibodies for Tfam
(1:1000, no. 850501) from BioLegend (San Diego, CA,
USA). The OXPHOS cocktail (1:1000, no. 110411) from
Abcam (Cambridge, UK) was used to blot for OXPHOS
proteins. All primary antibodies were diluted in Everyblot
blocking buffer and incubated overnight at 4°C. After
washing with tris buffered saline with Tween 20 (0.1%),
membranes were incubated for 1 hour at room tempera-
ture with goat anti-mouse secondary antibody (1:10 000 in
blocking solution, no. 31430) from Invitrogen. After wash-
ing steps with tris buffered saline with Tween 20, mem-
branes were incubated for 5 minutes with enhanced
chemiluminescence reagent (Clarity Western ECL sub-
strate, #170-5060, Bio-Rad) and exposed using a Chemi-
Doc MP Imaging System (Bio-Rad). Immunoblots were
quantified using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).15 Coomassie blue staining
was used to confirm equal loading and for densitometry
normalization.
Secondary analysis of publicly available data sets
Publicly available skeletal muscle microarray data sets for
CP (GSE31243),12 aging (GSE38718),16 and bed rest
(GSE148152)17 were used to determine shared signatures
in gene expression. The sampled muscles were not the
same in these studies: CP muscle (hamstrings muscle),
aging (biceps brachii), and bed rest (vastus lateralis mus-
cles). Raw data were downloaded and reanalyzed using
packages from the Bioconductor consortium. For each
array, raw intensity was preprocessed and normalized with
robust microarray analysis. Differentially expressed genes
were detected using a linear model implemented in R
package limma version 3.32.7 (Linear Model for Microar-
ray Data; R Foundation for Statistical Computing, Vienna,
Austria).18 The p-values were adjusted for multiple testing
by the Benjamini–Hochberg method to control the false
discovery rate. Differentially expressed genes were consid-
ered when the adjusted p-value was ≤0.05. Differentially
expressed gene lists were uploaded to g:Profiler for
pathway analysis and uploaded to Cytoscape version 3.8
for subsequent enrichment analysis and data visualization.19
Nodes were generated with an adjusted p<0.05 for enrich-
ment. The size of each node was scaled to the gene set
size; the shape of each node is specific to gene ontologies
(circle) or pathway (diamond) enrichment. The color of
the node was scaled to the adjusted p-value. Edges con-
necting nodes were scaled to the similarity coefficient (ge-
nes shared between nodes).
Statistical analysis
Statistical analysis was performed with Prism 8 (GraphPad
Software, CA, USA). Values are reported as mean (SD).
Differences in messenger RNA transcript levels, mtDNA
to genomic DNA ratio, and protein levels were assessed by
a Student’s t-test (data normality investigated with a
Shapiro–Wilk test). Significance level was set at p<0.05 for
a two-sided t-test.
Ethics
The ethical review board of Karolinska Institutet, Stock-
holm, Sweden, approved the study (Dnr 01-012, addendum
2018/1739-32, 04-324/2). The autopsy specimens were
collected in agreement with Swedish laws and regulations
on autopsy and transplantation with approval by the
National Board of Health and Welfare. Informed written
consent was obtained from all participants with CP and
the parents of those younger than 18 years.
RESULTS
To investigate oxidative capacity in CP muscle, we quanti-
fied levels of five OXPHOS proteins: complex I
(NDUFB8), complex II (SDHB), complex III (UQCRC2),
complex IV (COXII), and complex V (ATP5A). Four out
of five complexes (I, III, IV, V) showed a significant reduc-
tion of 20% to 37% (p<0.05) in content in CP muscle,
whereas complex II tended to be lower in CP but was not
statistically different to typically developing muscle
(33%, p=0.07; Fig. 1). We observed a lower mtDNA to
genomic DNA ratio (23%, p=0.002) in CP biceps brachii
muscle compared with typically developing biceps brachii
muscle (Fig. 2a). Skeletal muscle protein levels of Tfam
were not significantly different in CP muscle compared
with typically developing muscle (p=0.15, Fig 2b,c).
Consistent with evidence of reduced mitochondrial con-
tent, PGC1a gene expression was suppressed (24%, 1.60
[0.45] vs 0.84 [0.55], p=0.004) in CP muscle compared with
typically developing muscle (Fig. 3a). Splice variants dis-
played a non-homogenous expression in CP muscle;
PGC1a1 and PGC1a4 were reduced (36%, 1.15 [0.28]
vs 0.74 [0.54], p=0.05; 64%, 1.94 [0.84] vs 0.70 [0.53],
p<0.001 respectively) compared with typically developing
muscle, whereas PGC1a2 (69%, 0.42 [0.65] vs 0.13
[0.29], p=0.18) and PGC1a3 (+22, 0.53 [0.58] vs 0.65
[0.82], p=0.70) were not (Fig. 3b–e).
A secondary analysis of a publicly available microarray
data set comparing CP and typically developing hamstrings


















































































































Figure 1: Skeletal muscle oxidative phosphorylation (OXPHOS) protein levels in children with cerebral palsy (CP) compared with typically develop-
ing (TD) children. (a) Top: representative western blot. Bottom: Coomassie staining. (b) Quantification of complex I protein levels. (c) Quantification
of complex II protein levels. (d) Quantification of complex III protein levels. (e) Quantification of complex IV protein levels. (f) Quantification of
complex V protein levels. CP (n=9) and TD (n=9). OXPHOS protein band normalized to intensity of the whole lane on Coomassie-stained mem-
brane. Data expressed as relative to TD group mean. *Significantly different from TD, p<0.05. **Significantly different from TD, p<0.01
respectively.
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muscles12 produced 2290 significantly downregulated genes
in CP muscle. Gene ontology and pathway analyses
revealed glycolytic and mitochondrial transcriptional net-
works to be suppressed in CP skeletal muscle (Fig. 4a,b).
The gene set enriching the mitochondrial biogenesis node
is shown in Figure 4c and the gene set enriching the gly-
colytic transcriptional network is shown in Figure 4d. We
also compared the CP skeletal muscle transcriptome with
that of older adults16 and individuals subjected to pro-
longed bed rest17 to determine whether a similar metabolic
signature existed between conditions. CP shared more
genes with the aging data set (332 genes) compared with
the bed rest data set (109 genes). We found that 28 down-
regulated genes were shared between the three conditions
(Fig. S1, online supporting information) and that mito-
chondrial and aerobic respiration transcriptional networks
were suppressed under all three conditions (Fig. S2a,b,
online supporting information), including gene ontologies
(Reactome) such as mitochondrial translation initiation,
elongation, and termination (MRPS15, MRPL2, MRPL35)
and tricarboxylic acid cycle and electron transport chain
(CYCS, OGDH, SLC16A1, ATP5MPL, NNT, DLAT). For
a complete list of genes shared between CP and/or aging/





















































Figure 2: Skeletal muscle mitochondrial DNA abundance and transcription factor A (Tfam) protein levels in children with cerebral palsy (CP) compared
with typically developing (TD) children. (a) Ratio between mitochondrial (mt)DNA and nuclear DNA in TD (n=10) children and those with CP (n=18). The
mean value of the TD group was set as 100%. (b) Top: representative western blot; black arrow, non-specific band; open arrow, Tfam band. Bottom:
Coomassie staining. (c) Quantification of Tfam protein levels in children with CP (n=11) and the TD group (n=8). Tfam band normalized to intensity of






























































































































Figure 3: Gene expression of total PGC1a and splice variants PGC1-a1, a2, a3, and a4 in skeletal muscle of children with cerebral palsy (CP) compared
with typically developing (TD) children. (a) Total PGC1a (CP n=14, TD n=9). (b) PGC1a-1 (CP n=14, TD n=9). (c) PGC1a-2 (CP n=11, TD n=8, undetectable
in n=5 samples). (d) PGC1a-3 (CP n=10, TD n=8, undetectable in n=6 samples). (e) PGC1a-4, (CP n=14, TD n=9) in children with CP and the TD group.
Geometric mean of GAPDH, EMC7, and VCP was used for normalization of quantitative reverse transcription polymerase chain reaction. Specific gene
expression normalized to geometric mean of housekeeping genes expressed as AU. **Significantly different from TD, p<0.01. ***Significantly different
from TD, p<0.001.
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Figure 4: Mitochondrial and glycolytic signaling networks are suppressed in skeletal muscle of children with cerebral palsy (CP) compared with typi-
cally developing children. (a) Mitochondrial signaling network. (b) Glycolytic signaling network. (c) Gene list and expression levels of the gene set
enriching mitochondrial biogenesis. (d) Gene list and expression level of the gene sets enriching the glycolytic signaling network. Nodes were gener-
ated with an adjusted p<0.05 for enrichment. The size of each node was scaled to the gene set size; the shape of each node is specific to gene ontol-
ogy (circle) or pathway (diamond) enrichment. The color of the node was scaled to the adjusted p-value. Edges connecting nodes were scaled to the
similarity coefficient (genes shared between nodes). FC, fold change; GO, gene ontology.
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DISCUSSION
This study addresses biological processes involved in mito-
chondrial biogenesis, mtDNA content, and OXPHOS pro-
tein abundance in CP skeletal muscle. We show that key
upstream regulators of metabolism and mitochondrial bio-
genesis are reduced in CP skeletal muscle compared with
typically developing controls, and that this is associated
with downregulation of large gene networks affecting glu-
cose metabolism and mitochondrial biology. Skeletal mus-
cle in individuals with CP also contains lower amounts of
mtDNA, potentially indicating fewer mitochondria in CP
skeletal muscle compared with typically developing muscle.
Moreover, we also observed lower levels of OXPHOS pro-
teins in CP skeletal muscle that, together with reduced
overall mitochondrial content, suggests a reduced oxidative
capacity in CP muscle compared with typically developing
muscle.
PGC1a is a key regulator of mitochondrial biogenesis in
skeletal muscle.20 Transgenic mice that overexpress
PGC1a in skeletal muscle display an oxidative phenotype
with higher exercise tolerance than control mice and
greater mitochondrial content.21,22 On the contrary, several
studies that have used transgenic mice lacking PGC1a have
reported intact exercise adaptations including mitochon-
drial biogenesis,23–25 indicating a high level of biological
complexity that is still not fully elucidated. Acute exercise
studies in humans have also identified PGC1a as an early
response gene to aerobic exercise, preceding mitochondria-
related gene expression.26 PGC1a indirectly influences
mtDNA transcription via increased expression of mito-
chondrial Tfam, which is coactivated by nuclear respiratory
factor-1.20 In our study, we observed reduced abundance
of both total levels of PGC1a and isoforms PGC1a1 and
PGC1a4. PGC1a1 is believed to be the splice isoform
most involved in mitochondrial biogenesis,27 whereas
PGC1a4 has been implicated in skeletal muscle size regu-
lation.13 Contrasting data from two previous skeletal mus-
cle transcriptomics studies in children with CP,11,12 we did
not observe a significant reduction in Tfam protein in
skeletal muscle potentially owing to low sample number
for this specific analysis. In conjunction with these data, we
observed lower levels of mtDNA/genomic DNA, indicat-
ing fewer mitochondria in CP skeletal muscle than in typi-
cally developing muscle. Our skeletal muscle data are
supported by recent findings that children with CP also
have reduced mitochondrial content in peripheral blood
cells.28 Blood-based bioenergetic profiling correlates to
physical function in older individuals29 and has been sug-
gested as a proxy for skeletal muscle oxidative capacity.30
Taken together, our data suggest a reduced activity of
mitochondrial biogenesis in individuals with CP compared
with typically developing children.
Mitochondrial content in skeletal muscle has been linked
to aerobic capacity31,32 and shown to increase in response
to aerobic training.33 Individuals with CP have lower VO2
max than typically developing peers.34,35 Aerobic capacity
depends on central (cardiac output, ventilation) and
peripheral (perfusion, oxygen extraction, mitochondrial
content) factors. For individuals with CP, it is mostly
unknown how these parameters are influenced by increased
exercise intensity and thereby an increased demand for
energy (i.e. ATP). Interestingly, lactate production is
higher than expected at moderate exercise intensities in
individuals with CP, indicating that an insufficient ATP
production is evident already at relatively light exercise
intensities.36 The knowledge about metabolic capacity of
CP skeletal muscle is scarce. Transcriptomics studies have
indicated reduced expression of gene ontologies related to
oxidative metabolism.11,12 We observed reduced levels of
four out of five electron transport chain complexes (I, III,
IV, V) with only succinate dehydrogenase (II) not reaching
statistically significant levels. Interestingly, complex II does
not include any mtDNA encoded subunits, tentatively sug-
gesting that reduced mtDNA content primarily affects the
other complexes more as they are dependent on mitochon-
drially translated proteins. Our data support the previous
observation of a reduced aerobic capacity in skeletal muscle
and matches previously published fiber-type data from CP
biceps muscle that shows a shift to faster myosin isoforms
(IIx).10 Thus, our data suggest a role for decreased skeletal
muscle mitochondrial content and potentially also capacity
in the reduced exercise tolerance typically observed in indi-
viduals with CP.
Early metabolic dysregulation of skeletal muscle most
likely plays a role in the increased risk of metabolic and
cardiovascular disease that has been observed in the adult
population with CP.37,38 To gain further insight into
metabolism-related gene expression in CP skeletal muscle,
we performed a secondary analysis of publicly available
hamstrings muscle microarray data. A gene ontology analy-
sis (biological processes, reactome) on all significantly
downregulated genes showed that glucose metabolism- and
mitochondria-related gene networks were enriched in CP
muscle. Surprisingly, CP muscle shared more downregu-
lated genes with aged skeletal muscle than with long-term
disuse. This is intriguing and challenges the belief that CP
skeletal muscle pathophysiology is due to disuse per se and
suggests common mechanisms with aging, most likely
involving altered skeletal muscle neural input. We found
that 28 downregulated genes were shared between the
three conditions. Mitochondrial and aerobic respiration
transcriptional networks were suppressed under all three
conditions and out of the 28 common genes, 14 had mito-
chondrial localization as indicated by Mitocarta 3.0.39 This
focused analysis on gene expression supports the biochemi-
cal data presented in this paper and further suggests that
individuals with CP, already at a young age, display evi-
dence of metabolic dysregulation in skeletal muscle, as pre-
viously described with aging and long-term bed rest.17,40,41
Collectively, our findings stress the need for the develop-
ment of intervention strategies, including but not limited
to endurance exercise training performed at a sufficient
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frequency and intensity for children with the ability to vol-
untarily activate the muscle.42
The results of the current investigation should be viewed
in light of its limitations. Skeletal muscle samples from CP
were collected from children and adolescents with a fixed
contracture of the elbow flexors in most cases. Thus, our
findings related to mitochondrial abundance and capacity
in skeletal muscle from individuals with CP could be either
due to the pathophysiology of the contracture per se or a
more generalized feature of skeletal muscle in CP. We also
recognize the fact that our study focuses on just one mus-
cle which is a limitation for generalizability. Skeletal mus-
cle samples from the typically developing comparison
group were obtained post-mortem and represent a cumula-
tive sample of children and adolescents after an accidental
death. Thus, there was no age matching between CP and
typically developing children. It should also be noted that
we report measures of mtDNA/genomic DNA and
OXPHOS protein abundance in CP versus typically devel-
oping muscle. For a more complete picture, ideally mito-
chondrial function should also have been measured.
Moreover, the publicly available microarray data sets are
not sampled from the biceps muscle, and this should be
considered when comparing our biochemical data on
biceps muscle samples with the gene network analysis on
CP muscle (hamstrings muscle), aging, and bed rest (vastus
lateralis muscle).
In conclusion, we observed evidence of reduced mtDNA
and OXPHOS protein content in CP skeletal muscle, indi-
cating reduced mitochondrial abundance. Moreover,
transcriptional similarities to aging and long-term unload-
ing suggests signs of metabolic alterations in CP skeletal
muscle. Altogether, these aberrations in children with CP
potentially influence future metabolic health of individuals
with CP and tentatively contributes to the risk for meta-
bolic diseases such as type 2 diabetes.
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